{"id":55502,"date":"2026-01-26T20:44:06","date_gmt":"2026-01-26T12:44:06","guid":{"rendered":"https:\/\/flcube.com\/?p=55502"},"modified":"2026-01-26T20:44:07","modified_gmt":"2026-01-26T12:44:07","slug":"changchun-high-techs-gensci145-pi3k%ce%b1-inhibitor-cleared-by-nmpa-for-solid-tumor-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55502","title":{"rendered":"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study"},"content":{"rendered":"\n<p><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE:\u202f000661<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>clinical study<\/strong> for <strong>GenSci145<\/strong>, a <strong>mutation\u2011selective PI3K\u03b1 inhibitor<\/strong>, in patients with <strong>locally advanced or metastatic solid tumors harboring PIK3CA mutations<\/strong>, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>GenSci145 (mutation\u2011selective PI3K\u03b1 inhibitor)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Clinical Trial Approval (CTA)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced or metastatic solid tumors with PIK3CA mutations<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase\u202fI\/II<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Key Differentiator<\/strong><\/td><td>Selective for mutant PI3K\u03b1; avoids wild\u2011type inhibition\u2011related toxicities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>PI3K\u03b1<\/strong> (phosphatidylinositol 3\u2011kinase alpha) \u2013 key driver of tumor cell growth and anti\u2011apoptotic signaling in <strong>PIK3CA\u2011mutated cancers<\/strong><\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> Specifically inhibits <strong>PIK3CA hotspot mutations<\/strong> (e.g., H1047R, E545K) while <strong>sparing wild\u2011type PI3K\u03b1<\/strong>, minimizing off\u2011target metabolic effects<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong><\/li>\n\n\n\n<li><strong>Avoids hyperglycemia:<\/strong> Unlike non\u2011selective PI3K\u03b1 inhibitors (e.g., alpelisib), GenSci145 does not inhibit wild\u2011type PI3K\u03b1 in normal tissues<\/li>\n\n\n\n<li><strong>Blood\u2011brain barrier penetration:<\/strong> Demonstrates <strong>good CNS penetration<\/strong>, offering potential for <strong>brain metastases<\/strong><\/li>\n\n\n\n<li><strong>Improved tolerability:<\/strong> Preclinical data show <strong>no traditional side effects<\/strong> (hyperglycemia, rash, diarrhea) associated with first\u2011gen PI3K inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>GenSci145<\/th><th>Earlier\u2011Gen PI3K\u03b1 Inhibitors (e.g., Alpelisib)<\/th><\/tr><\/thead><tbody><tr><td><strong>PIK3CA Mutant Selectivity<\/strong><\/td><td>High (hotspot mutations)<\/td><td>Low (wild\u2011type + mutant)<\/td><\/tr><tr><td><strong>Wild\u2011Type PI3K\u03b1 Inhibition<\/strong><\/td><td>Minimal<\/td><td>Significant<\/td><\/tr><tr><td><strong>Hyperglycemia Risk<\/strong><\/td><td><strong>None observed<\/strong><\/td><td>High (dose\u2011limiting)<\/td><\/tr><tr><td><strong>Rash\/Diarrhea<\/strong><\/td><td><strong>Absent<\/strong><\/td><td>Common (Grade\u202f\u2265\u202f3: 20\u201130%)<\/td><\/tr><tr><td><strong>BBB Penetration<\/strong><\/td><td><strong>Good<\/strong><\/td><td>Poor<\/td><\/tr><tr><td><strong>Anti\u2011Tumor Activity<\/strong><\/td><td>Potent in PIK3CA\u2011mutant models<\/td><td>Moderate, limited by toxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>PIK3CA\u2011Mutated Solid Tumors<\/strong><\/td><td>280,000<\/td><td>1.1\u202fmillion<\/td><\/tr><tr><td><strong>Breast Cancer (PIK3CA\u2011mutant)<\/strong><\/td><td>95,000<\/td><td>420,000<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Alpelisib + fulvestrant (limited by hyperglycemia)<\/td><td><\/td><\/tr><tr><td><strong>GenSci145 Addressable Market<\/strong><\/td><td>85,000<\/td><td>380,000<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u00a56.5\u202fbillion<\/td><td>$4.2\u202fbillion<\/td><\/tr><tr><td><strong>Peak Market Share<\/strong><\/td><td>12\u202f%<\/td><td>5\u202f%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a5780\u202fmillion<\/td><td>$210\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alpelisib (Piqray, Novartis)<\/strong> \u2013 First\u2011gen PI3K\u03b1 inhibitor approved for HR+\/HER2\u2011 breast cancer; limited by <strong>metabolic toxicities<\/strong><\/li>\n\n\n\n<li><strong>Inavolisib (GDC\u20110077, Roche)<\/strong> \u2013 Selective PI3K\u03b1 inhibitor in Phase\u202fIII; no BBB penetration data<\/li>\n\n\n\n<li><strong>LOXO\u2011783 (Lilly)<\/strong> \u2013 PI3K\u03b1 H1047R\u2011selective inhibitor in Phase\u202fI\/II<\/li>\n\n\n\n<li><strong>GenSci145<\/strong> \u2013 <strong>First NMPA\u2011approved Chinese mutation\u2011selective PI3K\u03b1 inhibitor<\/strong> with <strong>BBB penetration<\/strong> and <strong>clean safety profile<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Changchun High\u2011Tech\u2019s <strong>Changchun biologics facility<\/strong> (capacity 8,000\u202fL) will produce clinical supply; <strong>GMP certification<\/strong> for small molecule completed in 2025<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Phase\u202fI\/II study initiation<\/strong> planned for <strong>Q2\u202f2026<\/strong>, focusing on <strong>PIK3CA\u2011mutant breast cancer and endometrial cancer<\/strong>; <strong>US IND filing<\/strong> targeted for <strong>H2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Planned studies with <strong>endocrine therapy<\/strong> (fulvestrant) and <strong>CDK4\/6 inhibitors<\/strong> to overcome resistance<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> Existing <strong>oncology sales force<\/strong> (1,200 reps) covering tier\u20112\/3 hospitals can support launch upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for GenSci145. Actual results may differ due to clinical trial outcomes, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-810c0e20-32ab-47d1-84ae-c3d310352593\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci145\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-810c0e20-32ab-47d1-84ae-c3d310352593\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,62,1171],"class_list":["post-55502","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products Administration (NMPA) has approved a clinical study for GenSci145, a mutation\u2011selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55502\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products Administration (NMPA) has approved a clinical study for GenSci145, a mutation\u2011selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55502\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T12:44:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T12:44:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55502#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55502\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study\",\"datePublished\":\"2026-01-26T12:44:06+00:00\",\"dateModified\":\"2026-01-26T12:44:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55502\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55502#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55502\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55502\",\"name\":\"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T12:44:06+00:00\",\"dateModified\":\"2026-01-26T12:44:07+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products Administration (NMPA) has approved a clinical study for GenSci145, a mutation\u2011selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55502#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55502\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55502#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products Administration (NMPA) has approved a clinical study for GenSci145, a mutation\u2011selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55502","og_locale":"en_US","og_type":"article","og_title":"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products Administration (NMPA) has approved a clinical study for GenSci145, a mutation\u2011selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.","og_url":"https:\/\/flcube.com\/?p=55502","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T12:44:06+00:00","article_modified_time":"2026-01-26T12:44:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55502#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55502"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study","datePublished":"2026-01-26T12:44:06+00:00","dateModified":"2026-01-26T12:44:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55502"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55502#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55502","url":"https:\/\/flcube.com\/?p=55502","name":"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T12:44:06+00:00","dateModified":"2026-01-26T12:44:07+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that China\u2019s National Medical Products Administration (NMPA) has approved a clinical study for GenSci145, a mutation\u2011selective PI3K\u03b1 inhibitor, in patients with locally advanced or metastatic solid tumors harboring PIK3CA mutations, addressing the toxicity limitations of earlier\u2011generation PI3K inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55502#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55502"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55502#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High\u2011Tech\u2019s GenSci145 PI3K\u03b1 Inhibitor Cleared by NMPA for Solid Tumor Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55502"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55502\/revisions"}],"predecessor-version":[{"id":55504,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55502\/revisions\/55504"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}